---
title: "LifeSci Capital Sticks to Its Buy Rating for Upstream Bio, Inc. (UPB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296003591.md"
description: "LifeSci Capital analyst Kate Dellorusso maintained a Buy rating on Upstream Bio, Inc. (UPB) with a $19 price target. Dellorusso holds a 3-star rating with a 7.9% average return. Other analysts include Truist Financial's Danielle Brill, who issued a Buy rating on August 12, and J.P. Morgan, which maintains a Hold rating."
datetime: "2026-08-15T14:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296003591.md)
  - [en](https://longbridge.com/en/news/296003591.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296003591.md)
generator: "portal-rs"
---

# LifeSci Capital Sticks to Its Buy Rating for Upstream Bio, Inc. (UPB)

In a report released today, Kate Dellorusso from LifeSci Capital maintained a Buy rating on Upstream Bio, Inc., with a price target of $19.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Dellorusso is a 3-star analyst with an average return of 7.9% and a 50.00% success rate. Dellorusso covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, Crinetics Pharmaceuticals, and Mereo Biopharma Group Plc.

In addition to LifeSci Capital, Upstream Bio, Inc. also received a Buy from Truist Financial’s Danielle Brill in a report issued on August 12. However, yesterday, J.P. Morgan maintained a Hold rating on Upstream Bio, Inc. (NASDAQ: UPB).

### Related Stocks

- [UPB.US](https://longbridge.com/en/quote/UPB.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)
- [MREO.US](https://longbridge.com/en/quote/MREO.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps](https://longbridge.com/en/news/297641472.md)
- [FDA-Supported Streamlined Phase 3 Program and Strong Long-Term Asthma Upside Underpin Buy Rating with Unchanged $19 Price Target](https://longbridge.com/en/news/297713150.md)
- [TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893](https://longbridge.com/en/news/297471640.md)
- [HC Wainwright Reaffirms Buy Rating for Cabaletta Bio (NASDAQ:CABA)](https://longbridge.com/en/news/297682437.md)
- [YD Bio Files First-Half 2026 Results, Reports Improved Equity Position](https://longbridge.com/en/news/297639743.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**